TABLE 2.
Activities of LY333328, teicoplanin, and vancomycin tested by microdilution in MH II broth against VRE strains
| Antibiotic | Phenotypea (no. of isolates) | MICs (μg/ml)
|
||
|---|---|---|---|---|
| 50% | 90% | Range | ||
| LY333328 | VanA (156) | 2 | 4 | 1–4 |
| VanA′b (16) | 1 | 2 | 0.25–4 | |
| VanB (17) | 0.25 | 1 | 0.125–2 | |
| Teicoplanin | VanA (156) | 64 | >128 | 32–>128 |
| VanA′b (16) | 16 | 16 | 16 | |
| VanB (17) | 0.5 | 2 | 0.25–8 | |
| Vancomycin | VanA (156) | 512 | 1,024 | 256–>1,024 |
| VanA′b (16) | 256 | 512 | 128–>1,024 | |
| VanB (17) | 256 | 256 | 64–1,024 | |
a
PCR analyses were predictive of VanA and VanB phenotypes.
b
VanA′ strains are highly resistant to vancomycin and intermediate in teicoplanin resistance (MIC = 16 μg/ml).